Compare Ascendis Pharma A/S (ASND) vs Prudential Financial Inc (PRU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Prudential Financial Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Prudential Financial Inc trades at $115.48 (market cap $40.07B). The key difference: Prudential Financial Inc is far larger — about 2.3× Ascendis Pharma A/S's market cap, and Prudential Financial Inc pays a 4.85% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PRU | |
|---|---|---|
Market Cap | $17.74B | $40.07B |
Sector | Health | Financials |
52-Week High | $277.18 | $118.72 |
52-Week Low | $163.32 | $92.00 |
Enterprise Value | $18.11B | $67.13B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PRU trades at $115.37, up 0.32% on the day, with a bullish technical signal and strong support at $113. The stock shows solid fundamentals with a P/E of 11.88 and net income margin of 5.5%, while recent earnings beats in Q1 2026 and dividend announcements highlight financial stability. News coverage emphasizes expansion in retirement products and international markets.
Outlook remains positive given valuation discounts and earnings momentum, though risks include volatile cash flows and high debt levels. Analyst consensus is cautious with a hold-heavy rating, but the stock's current technical strength and fundamental metrics support a steady growth trajectory for disciplined investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
